CATALENT, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 53.79 USD | +0.34% |
|
-1.88% | +19.72% |
| May. 29 | Catalent Shareholders Approve Deal With Novo Holdings | MT |
| May. 29 | Catalent stockholders approve deal with Novo Holdings | RE |
Financials (USD)
| Sales 2024 * | 4.34B | Sales 2025 * | 4.6B | Capitalization | 9.73B |
|---|---|---|---|---|---|
| Net income 2024 * | -896M | Net income 2025 * | 12M | EV / Sales 2024 * | 3.38 x |
| Net Debt 2024 * | 4.95B | Net Debt 2025 * | 4.48B | EV / Sales 2025 * | 3.09 x |
| P/E ratio 2024 * |
-10.9
x | P/E ratio 2025 * |
777
x | Employees | 17,800 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.83% |
More Fundamentals
* Assessed data
More news
Latest transcript on Catalent, Inc.
More recommendations
More press releases
More news
| 1 day | +0.34% | ||
| 1 week | -1.88% | ||
| 1 month | -3.69% | ||
| 3 months | -6.19% | ||
| 6 months | +38.46% | ||
| Current year | +19.72% |
1 week
53.51
54.97
1 month
53.5156.73
Current year
42.1160.20
1 year
31.8060.20
3 years
31.45142.64
5 years
31.04142.64
10 years
18.92142.64
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 52 | 10-09-30 | |
Matti Masanovich
DFI | Director of Finance/CFO | 52 | 23-07-04 |
Lim Chin Wei
CTO | Chief Tech/Sci/R&D Officer | - | 16-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Rolf Classon
BRD | Director/Board Member | 79 | 14-07-31 |
John Greisch
CHM | Chairman | 69 | 18-02-15 |
J. Carroll
BRD | Director/Board Member | 74 | 15-07-27 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.35% | 2 M€ | -.--% | ||
| 1.21% | 8 M€ | -.--% | ||
| 0.83% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 53.79 | +0.34% | 3,415,869 |
| 24-05-30 | 53.61 | +0.06% | 1,680,704 |
| 24-05-29 | 53.58 | -0.78% | 1,194,387 |
| 24-05-28 | 54 | -1.50% | 1,803,924 |
| 24-05-24 | 54.82 | +0.31% | 1,755,897 |
Delayed Quote Nyse, May 31, 2024 at 04:02 pm EDT
More quotes
Catalent, Inc. is specialized in pharmaceutical outsourcing services. The group offers solutions for the development and formulation of drugs, biological products and animal health products. Net sales break down by activity as follows:
- provision of development services and clinical supply services (55.4%);
- subcontracted manufacturing services (44.6%).
Net sales are distributed geographically as follows: the United States (63.2%), Europe (28.7%) and other (8.1%).
Sector
Pharmaceuticals
Calendar
2024-08-26
- Q4 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
53.79
USD
Average target price
63.5
USD
Spread / Average Target
+18.05%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +19.72% | 9.73B | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- CTLT Stock
